Abstract: The invention provides methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.

Abstract: An embodiment of the present invention is a separating agent wherein a group represented by a chemical formula of: or a group represented by a chemical formula of: is introduced on a surface thereof.

Abstract: A cationic bis-urea compound is disclosed of formula (1): wherein: each m is independently an integer of 0 to 4, each k is independently 0 or 1, each Z? is a monovalent radical independently selected from the group consisting of hydroxyl (*—OH), carboxyl (*—COOH), cyano (*—CN), nitro (*—NO2), sulfonate (*—SO3?), trifluoromethyl (*—CF3), halides, amine groups, ketone groups, alkyl groups comprising 1 to 6 carbons, alkoxy groups comprising 1 to 6 carbons, thioether groups comprising 1 to 6 carbons, and combinations thereof, each L? is independently a divalent alkylene group comprising 1 to 6 carbons, wherein a *-[-L?-]k- is a single bond when k is 0, each Y? is independently a monovalent non-polymeric radical comprising a positive charged amine, and each X? is independently a negative charged counterion.

Abstract: An embodiment of the present invention is a separating agent wherein a group represented by a chemical formula of: or a group represented by a chemical formula of: is introduced on a surface thereof.

Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

Abstract: Provided is a thermal responsive molecule favorable as a thermal responsive low-molecular hydrogelling agent or the like that gels in response to heat. The thermal responsive molecule is characterized in that an amphiphilic side chain obtained by bonding a hydrophilic side chain such as triethylene glycol and a hydrophobic group such as an octyl group is introduced into a C3-symmetric disc-shaped molecular skeleton such as 1,3,5-benzenetriyltriurea. For example, the thermal responsive molecule is 1,1?,1?-(benzene-1,3,5-triyl)tris{3-(2,5,8,11-tetraoxaheptadecan-17-yl)urea} or the like.

Abstract: A urea compound of the present invention is represented by general formula (I) shown below: wherein each of X1, X2 and X3 independently represents a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected from the group consisting of halogen groups, alkyl groups and alkoxy groups.

Abstract: The present invention provides compound(s) selected from the group of compounds represented by structural Formula (I): wherein X, Y and R1 are as described herein, use of such compounds as anaerobic cure accelerators, and compostions including such compounds.

Abstract: The present disclosure relates to new DNA-directed alkylating agents and water-soluble N-mustard agents with improved chemical stability and anti-tumor therapeutic efficacy.

Abstract: Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R1 is a rigid group, R2 is a hydrophilic group such that (A) is capable of self-assembly in water, and R3 is an organic group.

Abstract: A preparation of aryl carbamates can be achieved readily by carbonylation of an aromatic polyamine compound with diphenyl carbonate (DPC) using a combination of an organic acid and a tertiary amine as a catalyst. Aryl carbamate can be converted into 4,4?-diphenylmethane diisocyanate (MDI) by heating it at about 200 to about 230° C. in a non-polar solvent containing inhibitor such as benzoyl chloride. In another application, trans-ureation of biscarbamates with an amine or mixed amines is found to be extremely facile in a polar solvent such as dimethyl sulfoxide (DMSO) and tetramethylene sulfone (TMS) in absence of any catalyst to make polyurea polymers of high molecular weights. Thus, efficient green-chemistry processes based on biscarbamates in making isocyanate products as well as urea prepolymers, urea elastomers and urea plastics have been developed in all in excellent yields without using reactive phosgene or 4,4?-diphenylmethane diisocyanate separately in the trans-ureation polymerizations.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: The use of compounds in the treatment of skin disorders is described. In particular, the use of a compound of formula (I) or one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates or hydrates in the preparation of a medicament to treat inflammatory skin pathologies is described.

Abstract: The present invention provides a method for selectively placing carbon nanotubes on a substrate surface by using functionalized carbon nanotubes having an organic compound that is covalently bonded to such carbon nanotubes. The organic compound comprises at least two functional groups, the first of which is capable of forming covalent bonds with carbon nanotubes, and the second of which is capable of selectively bonding metal oxides. Such functionalized carbon nanotubes are contacted with a substrate surface that has at least one portion containing a metal oxide. The second functional group of the organic compound selectively bonds to the metal oxide, so as to selectively place the functionalized carbon nanotubes on the at least one portion of the substrate surface that comprises the metal oxide.

Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: New aniline or phenol N-mustards linked to DNA-affinity carriers (such as 9-anilinoacridines, acridines and quinolines), aminobenzamides or aminophenol ethers by a urea, carbamic acid, carbanic acid ester, hydrazineurea, hydrazinecarbamic acid ester, phenoxyurea, phenoxycarbamic acid ester linkage with improved chemical stability and anti-tumor therapeutic efficacy are provided.

Abstract: Process for preparing a composition by reacting a polyisocyanate, a monoalkoxy polyoxyalkylene monoamine and water. The composition and its use in making cellular products are claimed as well.

Abstract: The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4?) in the cocktail preparation of hydrophobic polymer membranes in ion selective electrode (ISE) or ion-sensitive field effect transistor (ISFET) chemical sensors for detection of monobasic phosphate (H2PO4) ionic species in soil, synthetic media, hydrophonic liquid, tree sap, ground water and rivers.

Abstract: The present invention is directed to compositions comprising organocatalysts that facilitate stereo-selective reactions and the method of their synthesis and use. Particularly, the invention relates to metal-free organocatalysts for facilitation of stereo-selective reactions, and the method of their synthesis and use.

Abstract: Nanostructures are formed from alkylated derivatives of aromatic acids of the formula: wherein at least one of R1 to R6 represents a carboxylic acid group, a primary amide group, an ester group, an amidine group, or a salt thereof, at least one other of R1 to R6 is X—Rc, and the remaining of R1 to R6 independently represent H or substituted or unsubstituted organic groups; X represents a linking group; and Rc represents a substituted or unsubstituted alkyl group.

Abstract: The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH2), substituted carbamoyl, carboxyl

Abstract: The present invention discloses a polymeric polyamine which can be produced by polymerizing polyoxyalkylene-amine and a linker. The linker can be anhydride, carboxylic acid, epoxy, isocyanate or poly(styrene-co-maleic anhydride) copolymers (SMA). The present invention also discloses a method for stabilizing the Ag nanoparticles with polymeric polyamine. The polymeric polyamine serving as a stabilizer or dispersant is mixed with a water solution of silver salt and then a reducer is provided to reduce the silver ions and form an organic or a water solution of Ag nanoparticles. Water or solvent of this solution can be further removed through a heating, freezing or decompression process, and thus solid content of the solution can be increased. The concentrated solution also can be diluted to obtain a stable dispersion without aggregation.

Abstract: A urea compound of the present invention is represented by general formula (1) shown below. [Each of X1, X2 and X3 independently represents a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected from the group consisting of halogen groups, alkyl groups and alkoxy groups.

Abstract: Provided is a thermal responsive molecule favorable as a thermal responsive low-molecular hydrogelling agent or the like that gels in response to heat. The thermal responsive molecule is characterized in that an amphiphilic side chain obtained by bonding a hydrophilic side chain such as triethylene glycol and a hydrophobic group such as an octyl group is introduced into a C3-symmetric disc-shaped molecular skeleton such as 1,3,5-benzenetriyltriurea. For example, the thermal responsive molecule is 1,1?,1?-(benzene-1,3,5-triyl)tris{3-(2,5,8,11-tetraoxaheptadecan-17-yl)urea} or the like.

Abstract: The present invention relates to substituted phenoxybenzamide compounds of general formula (I): in which R1, R2, R3, R4, R5, X, R6 and q are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Abstract: Novel biaromatic compounds having the general formula (I): and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/or of diseases related to the metabolism of lipids) or, alternatively, in cosmetic compositions.

Abstract: Disclosed herein are urea phenyl derivatives of the formula: wherein each R is an independently selected hydrocarbyl group and n is 2 or 3, and their use as nucleating agents for propylene polymers.

Abstract: In accordance with the present invention, there are provided a triphenylmethane derivative represented by the following general formula (1), an organic gelling agent containing the triphenylmethane derivative, an organic gel and an organic fiber. The triphenylmethane derivatives of the present invention can exhibit a capability of gelling various organic solvents even when used in a small amount notwithstanding these derivatives are low-molecular compounds. The resultant organic gel is useful as materials usable under a high-temperature condition such as chemomechanical system materials, impact and vibration absorbing materials, drug base materials, controlled drug-release materials, and silicone oil gels for solidification of electrolytic solutions and for cosmetics. In addition, an organic nanofiber can be produced from the triphenylmethane derivative by a simple process.

Abstract: This invention provides compounds of formula I: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: One aspect of the invention is a compound of formula (I) Ro-[L-(CqH2qS)pCrH2rRf]2??(I) wherein Ro is a divalent organic group having 2 to 40 carbon atoms; L is a linking group selected from —NHC(O)NH— or —C(O)NH— wherein the left side of the linking group is bonded to Ro; p is an integer of 0 or 1; q is an integer of 2 to 10; r is an integer of 1 to 10; and Rf is a linear or branched C1-C6 perfluoroalkyl group. Another aspect of the invention is a composite material comprising a porous support and a porous nanoweb, wherein said porous nanoweb comprises fibrous structures of between about 10 nm and about 1000 nm effective average fiber diameter as determined with electron microscopy; said fibrous structures being comprised of one or more compositions of formula (I). Another aspect of the invention is a method for making a composite material comprising a porous support and a porous nanoweb.

Abstract: A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

Abstract: The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH2), substituted carbamoyl, carboxyl

Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: The invention relates to compounds of formula (I), wherein R, R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.

Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

Abstract: The present invention provides intermediates, synthetic methods and novel urea compositions of matter.

Abstract: Lidocaine analogs, latex particle-analog conjugates, and methods of making and using the same. The analogs have the formula: wherein Z comprises a nucleophilic group and optionally a protecting group; L is a linker; R1, R2, R3, R4, R5 are each independently H, a protecting group, or C1 to C6 alkyls, provided that R1 and R3 may form a six membered ring with the nitrogen and carbon atom to which R1 and R3 are attached; R6 and R7 are each independently H or C1 to C20 alkyls; and including salts thereof. The analogs are immobilized on latex particles and prepared for use in assays for lidocaine.

Abstract: Compounds of the formulae wherein Z is —OR1, —SR1, —NR1R2, Y is —OR3, —SR3, or —NR3R4, at least one of R1, R2, R3, R4, R5, and R6 is hydrogen, at least one of R1, R2, R3, R4, R5, and R6 is other than hydrogen, at least one Z or Y within the compound is —NR1R2 or —NR3R4, R1, R2, R3, R4, R5, R6, and R7 each, independently of the others, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, and wherein R7 can also be alkoxy, aryloxy, arylalkyloxy, alkylaryloxy, polyalkyleneoxy, polyaryleneoxy, polyarylalkyleneoxy, polyalkylaryleneoxy, silyl, siloxane, polysilylene, polysiloxane, or wherein X is a direct bond, oxygen, sulfur, —NR40— wherein R40 is hydrogen, alkyl, aryl, arylalkyl, alkylaryl, or —CR50R60— wherein R50 and R60 each, independently of the other, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl.

Abstract: The present invention relates to a urea derivative of the formula (1) wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like].

Abstract: Compounds of the formulae wherein Z is OR1, SR1, or NR1R2, Y is OR3, SR3, or NR3R4, at least one of R1, R2, R3, R4, R5, and R6 is hydrogen, at least one of R1, R2, R3, R4, R5, and R6 is other than hydrogen, at least one Z or Y within the compound is NR1R2 or —NR3R4, R1, R2, R3, R4, R5, R6, and R7 each, independently of the others, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, and wherein R7 can also be (vi) an alkoxy, aryloxy, arylalkyloxy, alkylaryloxy, polyalkyleneoxy, polyaryleneoxy, polyarylalkyleneoxy, polyalkylaryleneoxy, silyl, siloxane, polysilylene, polysiloxane, or wherein X is a direct bond, oxygen, sulfur, NR40— wherein R40 is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, or CR50R60— wherein R50 and R60 each, independently of the other, is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, and wherein R6 can also be

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases

Abstract: In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor.

Abstract: Disclosed is a method for preparing a 2-hydroxy-6-ureidocarbonyl naphthalene derivative. The method comprises the step of reacting 2-hydroxy-6-aminocarbonyl naphthalene and a isocyanate in an organic solvent at a temperature of 90–200° C. According to the present invention, 2-hydroxy-6-ureidocarbonyl naphthalene derivative can easily be obtained within relatively short time and high yield.

Abstract: Compound of formula (I): and medicinal products containing the same are useful as dual ?2/5-HT2c antagonist receptors.

Abstract: The present invention provides N-aryloxypropanolyl-N?-phenethyl-urea derivatives of formula 3, method for their preparation and use thereof as potent appetite suppressants for treatment of obesity wherein R is selected from the group consisting of H, 2, 3 or 4-trifluoromethyl, 2, 3, or 4-chloro, 2, 3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl, and 4 formyl and X is S or O.

Abstract: The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is C?O, C?S, C?NH, (C?O)2 or SO2; and to processes for the preparation of these compounds and to their use in the treatment of protozoal diseases and to diseases where the inhibition of intracellular protein-degradation pathways is of benefit.

Abstract: Coating compositions contain hydroxyl- or carbamate functional resins with a relatively low equivalent weight. The resins are based on a polyol core containing urea and hydroxyl groups, and made by reacting a polyisocyanate, preferably a triisocyanate, with an amino functional polyol, preferably a polyol having one amino group and two or more hydroxyl groups. The polyol core may be further extended to a first or higher generation dendrimer or hyperbranched structure by reacting the initial polyol core with a compound having one carboxyl group and two or more hydroxyl groups.

Abstract: The present invention relates to novel imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.